Alimera readies for Iluvien resubmission, partner pSivida says
This article was originally published in Scrip
With approvals racking up in Europe for Iluvien (fluocinolone acetonide intravitreal insert) – most recently in Germany, Austria, France, Portugal and the UK – pSivida was eager to tell investors that its partner Alimera Sciences is ready to resubmit its application to FDA for marketing in the US, where the company has struggled to make it to the finish line with the drug as a treatment for diabetic macular edema (DME) (scripintelligence, 27 July 2012, 20 July 2012, 7 June 2012, 8 May 2012, 29 February 2012).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.